Regenecare HA Hydrogel Recalled
The product is being recalled because of Burkholderia cepecia contamination.
MPM Medical (Mesquite, TX) announced on Dec. 2, 2020 that it is voluntarily recalling one lot of Regenecare HA Hydrogel because of two customer complaints of visible contamination. The company stated in a press release that the product was contaminated with the bacteria, Burkholderia cepecia (B. cepacia).
Regenecare HA Hydrogel is a topical product is used for temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites or minor skin irritations. According to the company, use of product contaminated with B. cepacia could cause skin infections, which could spread into the blood stream in patients that are immunocompromised, leading to life-threatening sepsis.
The product is packaged in 3 oz. plastic tubes and was distributed nationwide to wholesalers and healthcare facilities in boxes of 12. The company has not received any reports of adverse events as of the date of the recall announcement. Adverse events may be reported to FDA through its MedWatch program.
Source: FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
